Fresenius Kabi has entered into an agreement to acquire Fenwal, Inc., a global provider specializing in separation technologies for blood and cell collection and therapy. Fresenius aims to offer customers a wider array of products and services, as well as increase product development and geographic expansion. The acquisition, subject to customary conditions, is expected to close by the end of the year. Financial terms were not disclosed.   “Fenwal has built a leadership position centered on sepa...